Merit Medical Systems is executing a disciplined margin expansion strategy, with gross margin reaching 51.4% in 2026Q2, up from 47.7% in 2024Q2, and operating margin expanding to 14.5% from 12.2% over the same period. The company is also benefiting from accele...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $1.19+24.1% vs $0.96 | $419M+3.4% vs $405M |
Q2 2026 Apr 30, 2026 | $0.94+11.9% vs $0.84 | $382M+1.1% vs $378M |
Q1 2026 Feb 24, 2026 | $1.04+8.3% vs $0.96 | $394M+1.0% vs $390M |
Q4 2025 Oct 30, 2025 | $0.92+12.2% vs $0.82 | $384M-1.1% vs $388M |
SOUTH JORDAN, Utah, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that management is scheduled to participate in the following upcoming investor conferences:
Jupiter Topco LLC bought a new position in shares of Merit Medical Systems, Inc. (NASDAQ: MMSI) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 27,531 shares of the medical instruments supplier's stock, valued at approximately $1,908,000. Several other hedge
Hsbc Holdings PLC purchased a new stake in shares of Merit Medical Systems, Inc. (NASDAQ: MMSI) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,983 shares of the medical instruments supplier's stock, valued at approximately $414,000. Several
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
Benchmark MMSI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Merit Medical Systems, Inc. (MMSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $87.07 | $5.19B | 40.88 | 11.66% | 8.48% | 8.67% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $0.70 | $48.57M | -0.60 | 15.4% | -747.19% | -94.35% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $20.24 | $1.49B | 6.13 | 18.52% | 80.56% | 30.03% | — |
Merit Medical Systems, Inc. (MMSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Merit Medical Systems, Inc. (MMSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 19, 2026·SEC
Apr 30, 2026·SEC
Get notified when MMSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Merit Medical Systems, Inc. (MMSI) stock FAQ — growth, dividends, profitability & financials explained
Merit Medical Systems, Inc. (MMSI) reported $1.58B in revenue for fiscal year 2025. This represents a 3027% increase from $50.5M in 1996.
Merit Medical Systems, Inc. (MMSI) grew revenue by 11.7% over the past year. This is steady growth.
Yes, Merit Medical Systems, Inc. (MMSI) is profitable, generating $145.6M in net income for fiscal year 2025 (8.5% net margin).
Merit Medical Systems, Inc. (MMSI) has a return on equity (ROE) of 8.7%. This is below average, suggesting room for improvement.
Merit Medical Systems, Inc. (MMSI) generated $203.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
